Core Viewpoint - Hong Kong's share-sale market has experienced a significant turnaround in 2023, becoming the leading fundraising hub in Asia, with share sales nearly quadrupling to over $73 billion, driven by strong demand from Chinese companies [1][2][3]. Group 1: Market Performance - Share sales in Hong Kong reached more than $73 billion through various methods, making it the top fundraising location in Asia for the first time since 2013, ranking just behind the US globally [2]. - The Hong Kong IPO pipeline is robust, with approximately 300 companies waiting to list, indicating a healthy market outlook [5]. - The Hang Seng Index has gained 29.5% this year, marking its best performance since 2017, although signs of weakness have emerged in the fourth quarter [11]. Group 2: Key Drivers - Chinese companies have been pivotal in driving the share-sale frenzy, with major listings such as Contemporary Amperex Technology Co. raising $5.3 billion, and both BYD Co. and Xiaomi Corp. raising over $5 billion each [3][8]. - The market has benefited from China's ambitions in artificial intelligence, biotechnology advancements, and efforts to boost domestic demand [8]. - Sectors aligned with China's strategic goals, such as technology and advanced manufacturing, are expected to remain active in pursuing IPOs [8]. Group 3: Future Outlook - Heavyweight candidates for future listings include companies like Syngenta Group and A.S. Watson Group, alongside potential listings from China's AI sector [9]. - The market's ability to absorb the upcoming supply of IPOs will depend on valuation and broader stock market performance [10]. - Despite the current optimism, there are concerns regarding the sustainability of high valuations, as many newly listed companies in India are trading below their debut prices [15].

[música] Os quería pedir antes que nada un favor a todos. Imaginad en vuestras cabezas la siguiente escena. Va saber que es muy sencilla.Es un día cualquiera. Suena el despertador. Son las 8 de la mañana.Te levantas. ¿Todavía te arrepientes de las últimas cervezas que te tomaste anoche. Pero te pones rápidamente tus mallas, tus zapatillas de correr y sales como cada mañana a correr alrededor, 5 km alrededor de tu casa.Vuelves, te duchas, desayunas y te pones a contestar emails que te han quedado en la bande ...

Core Insights - The research focuses on identifying asymmetrical risk/reward profiles within five key market themes: Semiconductor Supply Chain, Grid/Power/Energy Transition, Critical Materials, Biotechnology, and Artificial Intelligence/Cloud Computing [1] Group 1 - The investment strategy combines deep value investing principles with a forward-looking approach to uncover high-potential opportunities in the market [1] - The aim is to provide valuable perspectives and foster a community of investors who can share knowledge and insights [1]

Core Insights - Tonix Pharmaceuticals has appointed Irina Ishak as General Counsel, effective December 8, 2025, bringing over 25 years of experience in corporate legal and strategic leadership within the life sciences industry [1][2] - The company is focused on commercializing its marketed products and advancing its pipeline, with Ishak's expertise expected to be a significant asset in these efforts [2][3] Company Overview - Tonix Pharmaceuticals is a fully integrated biotechnology company with marketed products and a development pipeline [4] - The company markets TONMYA™, the first FDA-approved therapy for fibromyalgia in over 15 years, along with treatments for acute migraine [4] - Tonix's development portfolio targets central nervous system disorders, immunology, immuno-oncology, rare diseases, and infectious diseases [4] Recent Developments - The company has recently launched TONMYA™, which is a non-opioid analgesic for fibromyalgia, and is expanding its research into other conditions [3][4] - Tonix is also developing TNX-102 SL for acute stress reaction and major depressive disorder, and has a contract with the U.S. Department of Defense for TNX-4200, a broad-spectrum antiviral agent [4]

Core Viewpoint - Preformed Line Products (NASDAQ: PLPC) is identified as a mispriced beneficiary of the ongoing trend towards grid modernization and the rapid expansion of large-scale data centers, with the market currently undervaluing its growth potential [1] Group 1: Market Themes - The research focuses on key market themes to identify setups that offer asymmetrical risk/reward profiles within specific niches [1] - The investment portfolio is centered around five key themes: (1) Semiconductor Supply Chain, (2) Grid / Power / Energy Transition, (3) Critical Materials, (4) Biotechnology, and (5) Artificial Intelligence / Cloud Computing [1] Group 2: Investment Style - The investment style combines deep value investing principles with a forward-looking perspective to uncover highly asymmetric market opportunities [1] - The aim is to provide valuable insights and foster a community of investors who can share knowledge and benefit from each other's expertise [1]

Core Viewpoint - Preformed Line Products (NASDAQ: PLPC) is identified as a mispriced beneficiary of the ongoing trend towards grid modernization and the rapid expansion of large-scale data centers, with the market currently undervaluing its growth potential [1] Group 1: Market Themes - The research focuses on key market themes to identify setups that offer asymmetrical risk/reward profiles within specific niches [1] - The investment portfolio is centered around five key themes: (1) Semiconductor Supply Chain, (2) Grid / Power / Energy Transition, (3) Critical Materials, (4) Biotechnology, and (5) Artificial Intelligence / Cloud Computing [1] Group 2: Investment Style - The investment style combines deep value investing principles with a forward-looking perspective to uncover highly asymmetric market opportunities [1] - The aim is to provide valuable insights and foster a community of investors who can share knowledge and benefit from each other's expertise [1]

Core Viewpoint - Eli Lilly and Company has elected Carolyn R. Bertozzi, Ph.D., as a returning member of its board of directors, effective December 8, 2025, highlighting her significant contributions to targeted medicine development, particularly in oncology [1][2]. Group 1: Board Appointment - Carolyn R. Bertozzi, a Nobel Prize-winning chemist, will serve on the Science and Technology and Ethics and Compliance committees of Lilly's board [1][2]. - David A. Ricks, Lilly's chair and CEO, emphasized the value of Dr. Bertozzi's perspective as the company continues to innovate in oncology and immunology [2]. Group 2: Dr. Bertozzi's Background - Dr. Bertozzi is currently the Baker Family director of Sarafan ChEM-H and a professor at Stanford University, with additional roles in Chemical and Systems Biology and Radiology [2]. - She has received numerous honors and is an elected member of prestigious academies, including the National Academy of Medicine and the National Academy of Sciences [3]. Group 3: Company Overview - Eli Lilly has been a pioneer in medical discoveries for nearly 150 years, focusing on addressing significant health challenges such as diabetes, obesity, Alzheimer's disease, immune system disorders, and difficult-to-treat cancers [4]. - The company is committed to making its medicines accessible and affordable while ensuring diversity in clinical trials [4].

Industry Trends & Competitive Landscape - Biotech industry experienced a boom, but America's lead is slipping as China prioritizes synthetic biology [1] - Urgent need for strong American presence and young American leaders in the next generation of biotechnology [2] Scientific Advancements & Potential Breakthroughs - Lambert's project has the potential to be a major scientific breakthrough if further testing is successful [3] - A better diagnostic for Lyme disease has been developed, applicable beyond Lyme disease [3] Technology & Delivery Methods - Lipid nanoparticles are being considered as a delivery method [2]

Education & Talent - The biotechnology teacher acknowledges the students' exceptional intelligence, stating they are so smart that she struggles to keep up [1] - The program is described as "high-risk, high-reward," indicating a challenging but potentially very beneficial learning environment [1] - The lab is college-level, funded by taxpayers and donors, suggesting significant investment in resources [2] - Approximately 100 students compete for roughly 10 spots on the IGM team each year, highlighting the program's selectivity [2] Demographics & Competition - The student body is majority Asian-American, and the IGM team is entirely Asian-American, children of immigrants [2] - Families move to the district specifically for the biotech program and a chance to try out for the AEM team, indicating the program's reputation and draw [2] - Applicants submit a project proposal, take a test, and face an interview, outlining the rigorous selection process [2] - Skills like engineering or coding are beneficial, and long hours are required, emphasizing the dedication needed [3]

Group 1 - Pony AI Inc. reported a 3Q25 revenue of approximately $25.44 billion, representing a significant year-over-year increase of 72% [1] - The company experienced a non-GAAP EPS loss of –$0.14 [1] - A major contributor to the earnings growth was the Robotaxi segment, which generated substantial revenue [1]